FMFrancesco Menegale

Francesco Menegale

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francesco Menegale has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Risk assessment and perspectives of local transmission of chikungunya and dengue in Italy, a European forerunner

    by Francesco Menegale, Mattia Manica, Martina Del Manso, Antonino Bella, Agnese Zardini, Andrea Gobbi, Anna Domenica Mignuoli, Giovanna Mattei, Francesco Vairo, Luigi Vezzosi, et al.

    To address the growing frequency, extension, and size of local arboviral outbreaks in Europe we retrospectively analyzed dengue and chikungunya transmission in Italy from 2006 to 2023. We applied generalized additive models to the records of travel-related cases to highlight the spatiotemporal patterns of disease importation, calculated reproduction numbers for six local outbreaks based on autochthonous case data and mapped current transmission risks by applying a computational model that integrates human density, entomological, and climate data. Outbreak locations appear driven by case importation, which is notably higher for dengue – especially from June to October - rather than local transmission risks. Although reporting delays and favorable temperatures allowed onward transmission for several generations from mid-August to mid-November, upon outbreak detection control of transmission was achieved within 15 days. In high-risk areas, significantly longer epidemic risks were found for chikungunya (over 4 months). However, considering observed importation trends, increasingly frequent local dengue outbreaks are expected. Case detection should be prioritized focusing on areas, and in times, where environmental and climate conditions are permissive, regardless of prior outbreaks.


  • Open Access

    Quantifying West Nile virus circulation in the avian host population in Northern Italy

    by Alex De Nardi, Giovanni Marini, Ilaria Dorigatti, Roberto Rosà, Marco Tamba, Luca Gelmini, Alice Prosperi, Francesco Menegale, Piero Poletti, Mattia Calzolari, et al.

    West Nile virus (WNV) is one of the most threatening mosquito-borne pathogens in Italy where hundreds of human cases were recorded during the last decade. Here, we estimated the WNV incidence in the avian population in the Emilia-Romagna region through a modelling framework which enabled us to eventually assess the fraction of birds that present anti-WNV antibodies at the end of each epidemiological season.


  • Open Access

    Impact of routine prophylaxis with monoclonal antibodies and maternal immunisation to prevent respiratory syncytial virus hospitalisations, Lombardy region, Italy, 2024/25 season

    by Francesco Menegale, Luigi Vezzosi, Marcello Tirani, Simona Scarioni, Stefano Odelli, Federica Morani, Catia Borriello, Elena Pariani, Ilaria Dorigatti, Danilo Cereda, et al.

    Background: Respiratory syncytial virus (RSV) is a leading cause of hospitalisation in children worldwide. Recent regulatory approval of monoclonal antibody (mAb) nirsevimab for infants and the RSVpreF vaccine for pregnant women offers promising approaches to mitigate RSV-associated morbidity. Aim: To evaluate potential impacts of routine prophylactic campaigns (mAbs targeting infants or maternal vaccination) introduced in the 2024/25 season on hospitalisations from RSV lower respiratory tract infections in Lombardy, Italy. Methods: We used a catalytic model informed by data from pre-COVID-19 pandemic (before 2020) and post-pandemic periods (until 2022) to quantify the number of cases and hospitalisations that could be averted by seasonal nirsevimab administration to infants and RSVpreF maternal vaccination, considering changes in susceptibility caused by reduced RSV circulation during the pandemic. Results: As a marked proportion of RSV hospitalisations occurs in infants aged ≤ 1 year, seasonal mAb administration to 80% of newborns (uptake levels observed in Spain) was estimated to avert 50.2% (95% CI: 43.5–55.8) of hospitalisations in the total population. Coverage levels close to those observed for childhood vaccines (95%) could result in an additional average 18% reduction in hospitalisations. Vaccination of 65% of pregnant women, resembling the diphtheria–tetanus–pertussis vaccine coverage in Lombardy for this population, was estimated to avert 30.5% (95% CI: 19.6–39.7) of hospitalisations. At influenza vaccine coverage (12%), less than 8% of hospitalisations could be averted by maternal immunisation. Conclusion: Routine nirsevimab administration to infants demonstrates clear potential to reduce RSV-associated hospitalisations. Maternal immunisation can help in achieving high protection in at-risk populations.